MOVIMIENTO DE MUJERES POSITIVAS (MM+)

Email

movimientomujereslac@gmail.com

Phone

T: +50562252579

Web

https://www.movimientodemujerespositivas.org/

Address

RICARDO J ALFARO CIUDAD DE PANAMA PH CRISTAL HILLS Panama City 2320 Panama
About MOVIMIENTO DE MUJERES POSITIVAS (MM+)

The Positive Women’s Movement (MM+) was created on January 29, 1999 in Bogotá, Colombia, within the framework of the First Latin American and Caribbean Meeting of women living with and affected by HIV, with the purpose of joining forces through an alliance of organisations, in response to the growing “Feminisation” of the HIV epidemic. Currently, it has representatives from civil society organisations in 18 countries. With a focus on diversity, the MM+ is committed to working inclusively with the wide range of women in the region and establishing strategic alliances with actors who are traditionally not considered in the response to HIV, from a perspective based on human rights and recognising women, in all their diversity, as a key group.

In Panama, they participated in the first annual meeting with the national HIV and sexually transmitted infections program, in which they raised the importance of testing for hepatitis C and requested that hepatitis C be taken into consideration as a topic to be addressed not only in interconsultation but also included in the approach protocol.
On the other hand, the situation of the withdrawal of funds from PEPFAR and USAID has reduced the approach of peers, who were the only people working on the subject within the health services. This change in the dynamics will definitely mean a setback for the approach and the response of the State to hepatitis C.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close